Ligand Pharmaceuticals (LGND) revenue

Revenue · fiscal 2025
$268.09M

Ligand Pharmaceuticals (LGND) reported revenue of $268.09M in fiscal 2025 (the year ended December 31, 2025). That is 60.4% higher than the $167.13M of fiscal 2024. Figures as of 18 Nov 2026, 11:40 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$268.09M
Change on fiscal 2024
+60.4%
Growth, 5 years
+10.4% a year
Growth, 10 years
+14.1% a year
Highest on record
$268.09Mfiscal 2025
Lowest on record
$23.54Mfiscal 2010
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Ligand Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 10.4% a year; over ten years the rate was 14.1% a year. Across the 17 fiscal years on record (2009–2025), the highest was $268.09M in fiscal 2025 and the lowest $23.54M in fiscal 2010.

History · 17 fiscal years

Revenue by fiscal year

Ligand Pharmaceuticals revenue, year by year

Ligand Pharmaceuticals (LGND) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$268.09M 60.4% up
2024$167.13M 27.3% up
2023$131.31M 33.1% down
2022$196.25M 18.8% down
2021$241.54M 47.7% up
2020$163.56M 36.0% up
2019$120.28M 52.2% down
2018$251.45M 78.2% up
2017$141.10M 29.5% up
2016$108.97M 51.5% up
2015$71.91M 11.4% up
2014$64.54M 31.8% up
2013$48.97M 56.0% up
2012$31.39M 4.5% up
2011$30.04M 27.6% up
2010$23.54M 39.6% down
2009$38.94M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Ligand Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
RadNet RDNT$2.04B2025
Ligand Pharmaceuticals LGND$268.09M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on LGND

Ligand Pharmaceuticals, figure by figure

Ligand Pharmaceuticals (LGND) overview: price, valuation and scorecardAll health care companies by market value

Ligand Pharmaceuticals revenue: questions and answers

What is Ligand Pharmaceuticals's revenue?

Ligand Pharmaceuticals (LGND) reported revenue of $268.09M in fiscal 2025 (the year ended December 31, 2025). That is 60.4% higher than the $167.13M of fiscal 2024.

What is the growth rate of Ligand Pharmaceuticals's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 10.4% a year; over ten years the rate was 14.1% a year.

What are the highest and lowest revenue figures on record for Ligand Pharmaceuticals?

Across the 17 fiscal years on record (2009–2025), the highest was $268.09M in fiscal 2025 and the lowest $23.54M in fiscal 2010.

How is Ligand Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Ligand Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ligand Pharmaceuticals (LGND) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/LGND/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.